Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-depe...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Hong, Chan, Abigael G., Ahene, Ago, Bellovin, David I., Deng, Rong, Hsu, Amy W., Jeffry, Ursula, Palencia, Servando, Powers, Janine, Zanghi, James, Collins, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565817/
https://www.ncbi.nlm.nih.gov/pubmed/34719330
http://dx.doi.org/10.1080/19420862.2021.1981202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565817/
https://www.ncbi.nlm.nih.gov/pubmed/34719330
http://dx.doi.org/10.1080/19420862.2021.1981202

Ejemplares similares